AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03673852 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Health Home Enrollment
Description: A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
Study NCT00905411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PacDASH intervention
Description: Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study.
Study NCT06055101 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DEXMEDETOMIDINE
Description: DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water.
Study NCT06055101 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neostigmine
Description: Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
Study NCT06055101 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane.
Study NCT00212836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg by mouth once daily for 26 weeks
Study NCT03822637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine + albuterol
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.
Study NCT03822637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline + albuterol
Description: Normal saline is a placebo agent and Albuterol is a bronchodilator.
Study NCT01921387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC transplant
Study NCT01921387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT01921387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01921387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01921387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01921387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01921387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSC transplant
Study NCT01923883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Description: EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
Study NCT01921387 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Description: Given IV
Study NCT00304746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
Study NCT00304746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00225069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of sympathectomy
Description: T2 sympathectomy or T2-T3 sympathectomy
Study NCT03723005 — intervention group
Intervention type: DEVICE
Intervention: Neolight Phototherapy Mattress
Description: Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
Study NCT03723005 — intervention group
Intervention type: DEVICE
Intervention: Standard-of-Care
Description: Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
Study NCT03895112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID200
Description: dose cohorts of 21-day cycles
Study NCT01668030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzymatic agent
Description: Enzymatic agent
Study NCT01668030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacitracin
Study NCT03173586 — intervention group
Intervention type: OTHER
Intervention: Sugar sweetened beverage (SSB)
Description: This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
Study NCT01103778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade®)
Description: Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
Study NCT01102218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Standard of Care
Study NCT01102218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: Standard of Care
Study NCT01102218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg qd po for 6 months
Study NCT02483078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study NCT01547364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of 10 ml of normal saline into the caudal epidural space
Study NCT01547364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: Injection of 10 ml or dextrose 5% in water into the caudal epidural space
Study NCT01366092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
Study NCT04680234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMEP kit
Description: Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
Study NCT04680234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermapen
Description: Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
Study NCT01618136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7449 alone
Description: Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
Study NCT01618136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7449 plus TMZ
Description: Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
Study NCT01618136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7449 plus carboplatin and paclitaxel
Description: Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
Study NCT01923883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
Study NCT01923883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echoendoscope Olympus GF-UCT240
Study NCT01923883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echoendoscope Olympus GF-UCT240
Study NCT02283294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02283294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT00771381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAZA PET scan
Description: Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
Study NCT00771381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluGlucoScan Injection (18F-FDB) PET scan
Description: Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
Study NCT02158312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)
Description: 2 mA for 20 minutes transcranial direct current stimulation
Study NCT01394952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered subcutaneously
Study NCT01394952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT00584844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live F tularensis Vaccine
Description: Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
Study NCT00700323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PS-Omega3 conjugate supplementation
Study NCT05086861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oesophageal pacing after left atrial posterior wall isolation
Description: Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
Study NCT01808378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded adipose-derived stem cells
Description: Local injection of autologousadipose derived stem cells
Study NCT02258802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
Study NCT02465931 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paper and Pencil Informed Consent
Description: Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
Study NCT00700323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00349726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol lower volume
Description: 60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Study NCT00349726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol higher volume
Description: 120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Study NCT02465931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Informed Consent Tool
Description: Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
Study NCT01071408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroke prevention care program
Description: Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
Study NCT02621632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: (Socknleg)To done of a novel compression system
Description: To done a novel compression system.
Study NCT02483078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02483078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Background Regimen
Description: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Study NCT02483078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optimized Background Regimen
Description: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Study NCT01536106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Bone marrow mononuclear cells
Description: Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
Study NCT01536106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Intracoronary infusion of autologous peripheral blood.
Study NCT03067129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir Adult Formulation
Description: Co-formulated film-coated tablet (100 mg/40 mg)
Study NCT03067129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir + Pibrentasvir Pediatric Formulation
Description: Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
Study NCT01577602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed medication list
Description: Provide a list of patient's current medication list as noted in the EMR
Study NCT01577602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open ended question
Description: medical assistants begin medication reconciliation with a scripted open ended question.
Study NCT01577602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: Combines the printed medication list with the open ended question
Study NCT03423602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQseal®
Description: Large hole closure system
Study NCT04470388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral Capsule
Study NCT04470388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-514
Study NCT01941602 — intervention group
Intervention type: DRUG
Intervention: prophylactic enoxaparin
Description: enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
Study NCT01941602 — intervention group
Intervention type: PROCEDURE
Intervention: non-prophylactic
Description: no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
Study NCT02780479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: at 24 hours from the first Dexamethasone dose given in ED.
Study NCT02780479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: at 24 hours from the first Dexamethasone dose given in ED.
Study NCT05118542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propylthiouracil
Description: PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
Study NCT05118542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
Study NCT04031404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse TMS
Description: Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
Study NCT03645889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLTG
Description: A combination of 13 herbal granules
Study NCT03645889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 90% starch filler and 10% PLTG
Study NCT03956888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents